Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.50 |
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30173097 | 1.00 | CDK1 (0.50) | CDK1YTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL183035 | 0.81 | CDK1 (0.68) | CDK1YTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL29426225 | 0.81 | CDK1 (0.68) | CDK1YTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL7289687 | 0.79 | CDK1 (0.51) | CDK1YTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL23027205 | 0.78 | CDK1 (0.42) | CDK1YTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL130527 | 0.78 | CDK1 (0.64) | CDK1YTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL764036 | 0.78 | CDK1 (0.59) | CDK1YTHDC1ADORA2AADORA1CCNE1 | |
| SCHEMBL380974 | 0.78 | CDK1 (0.50) | CDK1YTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL8510719 | 0.77 | PDE4A (0.63) | CDK1YTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL1293109 | 0.77 | CDK2 (0.49) | CDK1ADORA2AADORA1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-07-25 | — | — | US | disclosed |
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023014988-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | RAYZEBIO, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| EP-2265626-B1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | LCB PHARMA INC (CA) | 2019-05-15 | — | — | EP | disclosed |
| US-20180258090-A1 | IMAGING AGENTS FOR NEURAL FLUX | UNITED STATES DEPARTMENT OF ENERGY | 2018-09-13 | — | — | US | disclosed |
| US-9790252-B2 | 2-fluorinated riboses and arabinoses and methods of use and synthesis | CORNELL UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| US-8846636-B2 | Nucleoside analogues with quaternary carbon stereogenic centers and methods of use | LCB PHARMA INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20120108535-A1 | 2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS | CORNELL UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20020103161-A1 | Novel heterocycles | ARIAD PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CDK1 2/4885YTHDC1 2627/4885PDE4A 1029/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | CDK1 2/4885YTHDC1 2627/4885PDE4A 1029/4885 |
| US-20020103161-A1 | Novel heterocycles | BMP2, SOST, BMP4 | CDK1 93/4885YTHDC1 3944/4885PDE4A 303/4885 |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CDK1 2/4885YTHDC1 2627/4885PDE4A 1029/4885 |
| US-10519160-B2 | Imaging agents for neural flux | SLC18A2, SLC18A3, PMP22 | CDK1 2522/4885YTHDC1 4749/4885PDE4A 2450/4885 |
| US-20120108535-A1 | 2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS | SLC2A2, SLC29A2, DERA | CDK1 2348/4885YTHDC1 478/4885PDE4A 1850/4885 |
| US-20180258090-A1 | IMAGING AGENTS FOR NEURAL FLUX | SLC18A2, SLC18A3, PMP22 | CDK1 2522/4885YTHDC1 4749/4885PDE4A 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.